HK Stock Market Move | TRANSTHERA-B (02617) rises by more than 60% again, nearly 10 times higher since listing. Beishui increased its holdings by over 300 million Hong Kong dollars in the past two days.

TRANSTHERA-B(02617) rose by over 60% in the morning session, reaching a high of 679.5 Hong Kong dollars, with a cumulative increase of nearly 10 times since its listing. As of the time of writing, it has risen by 50.6%, reaching 625.5 Hong Kong dollars, with a trading volume of 1.177 billion Hong Kong dollars, and a total market value once exceeding 250 billion Hong Kong dollars. On the news front, the Shanghai and Shenzhen stock exchanges recently announced that Pharmaron Health had been included in the list of stocks eligible for trading under the Hong Kong Stock Connect, effective September 8th. Data shows that after being included in the Connect, Beishui Capital has been continuously increasing its holdings of Pharmaron Health, adding 180 million and 142 million Hong Kong dollars on September 12 and September 15, respectively. Public information shows that Pharmaron Health is focused on discovering and developing innovative small molecule therapies for tumors, inflammation, and cardiovascular metabolic diseases. As of June 30, 2025, the company's main pipeline includes six clinical stage candidate products and multiple preclinical stage candidate products. It is worth noting that Pharmaron Health announced its interim performance earlier, showing that the group did not generate any revenue from its main business in the first half of the year, with other income and gains decreasing from 10.4 million yuan in the first half of 2024 to 3.6 million yuan, a decrease of 65.1%. In addition, the company's core product, Tiragantine (TT-00420), has recently received multiple positive developments.